Tirzepatide has emerged as a groundbreaking therapy for type 2 diabetes, offering promising outcomes. However, the expense of this innovative drug and its supply have become key concerns for patients and healthcare practitioners. While tirzepatide has been authorized by regulatory agencies, its costly nature presents a significant obstacle to many